Quality of life in the treatment of parkinson's disease;Lebensqualität als ziel therapeutischer interventionen bei morbus parkinson

Aktuelle Neurologie, Supplement

Volumn 36, Issue SUPPL.1, 2009, Pages

  Herzog, J ^a   Deuschl, G ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Deep brain stimulation; Parkinson's disease; Pharmacology; Quality of life

Indexed keywords

AKINESIA; ARTICLE; BRAIN DEPTH STIMULATION; DISEASE DURATION; DISEASE SEVERITY; DYSKINESIA; EVIDENCE BASED MEDICINE; INSOMNIA; MENTAL DISEASE; PALLIDOTOMY; PARKINSON DISEASE; QUALITY OF LIFE;

EID: 78649320993     PISSN: 14372754     EISSN: 16117697     Source Type: Journal    
DOI: 10.1055/s-0028-1090175     Document Type: Article

References (51)

1. Lee MA, Walker RW, Hildreth AJ et al. Individualized assessment of quality of life in idiopathic Parkinson's diseas (Pubitemid 44848940)
2. Welsh MD. Measurement of quality of life in neurodegenerative disor- ders. Curr Neurol Neurosci Rep 2001; 1: 346-349
3. Chapuis S, Ouchchane L, Metz O et al. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005; 20: 224-230 (Pubitemid 40361128)
4. Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson's disease? Psychol Med 2001; 31: 65-73 (Pubitemid 32046737)
5. Witjas T, Kaphan E, Azulay JP. Non-motor fluctuations in Parkinson's disease. Rev Neurol (Paris) 2007; 163: 846-850 (Pubitemid 47413778)
6. The World Health Organization Quality of Life assessment (WHOQOL). Position paper from the World Health Organization. Soc Sci Med 1995; 41: 1403-1409
7. Greer S. The psychological dimension in cancer treatment. Soc Sci Med 1984; 18: 345-349
8. Browne JP, O'Boyle CA, McGee HM et al. Individual quality of life in the healthy elderly. Qual Life Res 1994; 3: 235-244 (Pubitemid 24301631)
9. Neudert C, Wasner M, Borasio GD. Patients' assessment of quality of life instruments: a randomised study of SIP, SF-36 and SEIQoL-DW in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 103-109 (Pubitemid 33035901)
10. Den Oudsten BL, Van Heck GL, De Vries J. Quality of life and related con- cepts inParkinson's disease: a systematic review. Mov Disord 2007; 22: 1528-1537 (Pubitemid 47477911)
11. Haave E, Hyland ME, Skumlien S. The relation between measures of health status andquality of life in COPD. Chron Respir Dis 2006; 3: 195-199 (Pubitemid 44863107)
12. Ware JE Jr. Conceptualization and measurement of health-related quality of life: comments on an evolving field. Arch Phys Med Rehabil 2003; 84, 4 (Suppl. 2): S43-51 (Pubitemid 36417642)
13. Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985; 35: 185-188
14. Bergner M, Bobbitt RA, Carter WB et al. The Sickness Impact Profile: de- velopment and final revision of a health status measure. Med Care 1981; 19: 787-805 (Pubitemid 11021288)
15. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483
16. Haapaniemi TH, Sotaniemi KA, Sintonen H et al. The generic 15D instru- ment is valid and feasible for measuring health related quality of life in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 976-983 (Pubitemid 38869609)
17. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208
18. de Boer AG, Wijker W, Speelman JD et al. Quality of life in patients with Parkinson's disease: development of a questionnaire. J Neurol Neuro-surg Psychiatry 1996; 61: 70-74 (Pubitemid 26232031)
19. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the develop- ment, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998; 245 (Suppl. 1): 10-14
20. Calne SM, Mak E, Hall J et al. Validating a quality-of-life scale in care- givers of patients with Parkinson's disease: Parkinson's Impact Scale (PIMS). Adv Neurol 2003; 91: 115-122
21. Welsh M, McDermott MP, Holloway RG et al. Development and testing of the Parkinson's disease quality of life scale. Mov Disord 2003; 18: 637-645 (Pubitemid 36790278)
22. Hagell P, Nygren C. The 39 item Parkinson's disease questionnaire (PDQ-39) revisited: implications for evidence based medicine. J Neu- rol Neurosurg Psychiatry 2007; 78: 1191-1198 (Pubitemid 350057280)
23. Damiano AM, McGrath MM, Willian MK et al. Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual Life Res 2000; 9: 87-100 (Pubitemid 30670652)
24. Fitzpatrick R, Peto V, Jenkinson C et al. Health-related quality of life in Parkinson's disease: a study of outpatient clinic attenders. Mov Dis- ord 1997; 12: 916-922 (Pubitemid 27496768)
25. Kuopio AM, Marttila RJ, Helenius H et al. The quality of life in Parkin- son's disease. Mov Disord 2000; 15: 216-223 (Pubitemid 30166726)
26. Martinez-Martin P, Frades Payo B, Fontan Tirado C et al. Assessing qual- ity of life in Parkinson's disease using the PDQ-39. A pilot study. Neurologia 1997; 12: 56-60 (Pubitemid 27160120)
27. Lyons KE, Pahwa R, Troster AI et al. A comparison of Parkinson's disease symptoms and self-reported functioning and well being. Parkinso- nism Relat Disord 1997; 3: 207-209 (Pubitemid 28188831)
28. Rubenstein LM, Voelker MD, Chrischilles EA et al. The usefulness of the Functional Status Questionnaire and Medical Outcomes Study Short- Form in Parkinson's disease research. Qual Life Res 1998; 7: 279-290 (Pubitemid 28207017)
29. Karlsen KH, Larsen JP, Tandberg E et al. Quality of life measurements in patients with Parkinson's disease: A community-based study. Eur J Neurol 1998; 5: 443-450 (Pubitemid 28469997)
30. Caap-Ahlgren M, Dehlin O. Insomnia and depressive symptoms in patients with Parkinson's disease. Relationship to health-related quality of life. An interview study of patients living at home. Arch Gerontol Geriatr 2001; 32: 23-33 (Pubitemid 32201141)
31. Hobson P, Holden A, Meara J. Measuring the impact of Parkinson's disease with the Parkinson's Disease Quality of Life questionnaire. Age Ageing 1999; 28: 341-346 (Pubitemid 29346827)
32. Karlsen KH, Larsen JP, Tandberg E et al. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 66: 431-435 (Pubitemid 29145675)
33. Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci 2006; 248: 151-157 (Pubitemid 44647306)
34. Moore O, Peretz C, Giladi N. Freezing of gait affects quality of life of peoples with Parkinson's disease beyond its relationships with mobility and gait. Mov Disord 2007; 22: 2192-2195
35. Muslimovic D, Post B, Speelman JD et al. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology 2008; 70: 2241-2247
36. Martinez-Martin P, Deuschl G. Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease. Mov Dis- ord 2007; 22: 757-765 (Pubitemid 46804926)
37. Grandas F, Martinez-Martin P, Linazasoro G. Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Si- nemet CR: the STAR Study. The STAR Multicenter Study Group. J Neu- rol 1998; 245 (Suppl. 1): S31-33 (Pubitemid 28230764)
38. Martinez-Martin P, Grandas F, Linazasoro G et al. Conversion to controlled-release levodopa/carbidopa treatment and quality of life as measured by the Nottingham Health Profile. The STAR Study Group. Neurologia 1999; 14: 338-343 (Pubitemid 29516860)
39. Durif F, Devaux I, Pere JJ et al. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol 2001; 45: 111-118 (Pubitemid 32215799)
40. Gershanik O, Emre M, Bernhard G et al. Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally con- trolled with levodopa alone, in daily clinical practice: an internation- al, multicentre, open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 963-971 (Pubitemid 37141384)
41. Koller W, Guarnieri M, Hubble J et al. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapo- ne) in Parkinson's disease patients experiencing wearing-off. J Neural Transm 2005; 112: 221-230 (Pubitemid 40179116)
42. Onofrj M, Thomas A, Vingerhoets F et al. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkin- son's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. J Neural Transm 2004; 111: 1053-1063 (Pubitemid 39037126)
43. Koller W, Lees A, Doder M et al. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov Disord 2001; 16: 858-866 (Pubitemid 36041187)
44. Welsh MD, Dorflinger E, Chernik D et al. Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone. Mov Disord 2000; 15: 497-502 (Pubitemid 30333222)
45. Holloway RG, Shoulson I, Fahn S et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044-1053 (Pubitemid 38915945)
46. Baas HK, Schueler P. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease. Eur Neurol 2001; 46 (Suppl. 1): 18-23 (Pubitemid 34008779)
47. Biglan KM, Schwid S, Eberly S et al. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord 2006; 21: 616-623 (Pubitemid 43840530)
48. Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006; 355: 896-908 (Pubitemid 44315982)
49. Esselink RA, de Bie RM, de Haan RJ et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. Neurology 2004; 62: 201-207 (Pubitemid 38167125)
50. Just H, Ostergaard K. Health-related quality of life in patients with ad- vanced Parkinson's disease treated with deep brain stimulation of the subthalamic nuclei. Mov Disord 2002; 17: 539-545 (Pubitemid 36040969)
51. Kleiner-Fisman G, Herzog J, Fisman DN et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006; 21 (Suppl. 14): S290-304 (Pubitemid 44028288)